The retinoblastoma tumor suppressor, RB, is a key regulator of cellular proliferation that is functionally inactivated at high frequency in human cancer. Although RB has been extensively studied with regard to tumor etiology, loss of tumor-suppressor function often occurs relatively late in tumor progression. Therefore, inactivation of RB could have a profound impact on the behavior of tumors driven by discrete oncogenes. Here, collaboration between Ras or c-Myc deregulation and RB functional state was investigated in a model of conditional genetic deletion to decipher the effects related to disease progression. These studies showed that RB loss had a robust impact on mitogen dependence, anchorage dependence and overall survival, which was significantly modified by oncogene activation. Specifically, RB deficiency predisposed c-Myc-expressing cells to cell death and reduced overall tumorigenic proliferation. In contrast, RB deficiency exacerbated the tumorigenic behavior of Ras-transformed cells in both the model system and human tumor cell lines. As these tumors exhibited highly aggressive behavior, the possibility of exploiting the intrinsic sensitivity to cell death with RB loss was evaluated. Particularly, although Ras-transformed, RB-deficient cells bypassed the G1-checkpoint elicited by pharmacological activation of the p53 pathway, they were also highly sensitized to cell death. Altogether, these data suggest that the impact of RB deletion is dependent on the oncogene milieu, and can directly contribute to transformed phenotypes and response to therapeutic intervention.
Introduction
Cancer is a highly heterogeneous disease, wherein complex genetic interactions contribute to the overall disease phenotype. A multitude of studies indicate that tumor development and progression is dependent on multiple events, which mediate disease severity (Hanahan and Weinberg, 2000) . In particular, most tumors exhibit a combination of tumor-suppressor dysfunction coupled with oncogene activation. Such cooperation has long been analysed in the context of oncogenic transformation in fibroblastic models (Zhu et al., 1998; Groth et al., 2000; Mallette et al., 2004; MacPherson et al., 2007) . However, the relative contribution and specificity of such events to existing tumor phenotypes has not been well delineated. In this context, although the retinoblastoma tumor suppressor (RB) has been extensively studied with regard to tumor etiology, surprisingly little is known regarding how RB dysregulation can modify tumor behavior/disease progression or modulate cellular response downstream of discrete oncogenes. The idea that RB status could have an important role with regard to established tumors is supported by observations that RB loss often occurs as a relatively late event during disease progression and is frequently correlated with poor prognosis (Miyamoto et al., 1996; Seeley et al., 2007; Burkhart and Sage, 2008) .
The RB tumor-suppressor pathway represents one of the most frequently inactivated signaling axes in human cancer (Lee et al., 1988; Horowitz et al., 1990; Hanahan and Weinberg, 2000; Knudsen and Knudsen, 2008) . Proximally, the RB protein functions as a transcriptional repressor of the E2F family of transcription factors (Nevins, 2001; Dynlacht, 2004, 2007; Cobrinik, 2005) . In doing so, RB restricts the expression of a transcriptional program that includes key regulators of cell cycle progression (for example, cyclin A and cyclin-dependent kinase (CDK) 2), DNA replication (for example, MCM7 and PCNA) and mitosis (for example, Plk1 and MAD2) (Nevins, 2001; Markey et al., 2002 Markey et al., , 2007 Dynlacht, 2004, 2007; Cobrinik, 2005; Iaquinta and Lees, 2007) . Mitogenic signals lead to the activation of CDK/cyclin complexes that phosphorylate RB, alleviating the latent transcriptional repression and allowing for progression through the cell cycle (Weinberg, 1995; Peeper et al., 1997; Dyson, 1998) . Conversely, multiple signaling networks responsive to cellular stresses inhibit cell cycle progression by preventing RB phosphorylation and promoting subsequent maintenance of transcriptional repression elicited by RB (Wang et al., 1994; Cobrinik, 2005; Burkhart and Sage, 2008; Knudsen and Knudsen, 2008) . Thus, control of the RB/E2F pathway is highly and directly responsive to signaling pathways that modulate CDK/cyclin activity. The coordination of these events is critical for the appropriate regulation of cell cycle progression, and ultimately cell division. Not surprisingly, disruption of these processes is prominent in human cancers. In this context, although direct loss of the RB gene is observed in specific tumor types, many tumors are believed to aberrantly inactivate the RB protein through posttranslational mechanisms (Burkhart and Sage, 2008) . Among these influential signaling cascades affecting RB are a variety of oncogenes that are well documented to be frequently activated in human cancers (Bos, 1989; Alkarain and Slingerland, 2004; Knudsen and Knudsen, 2008) .
The Ras oncogene is believed to influence cellular proliferation principally through the cyclin D1/RB/E2F axis and is among the most prominent and wellcharacterized oncogenes aberrantly activated in human cancers (Bos, 1989; Berkovich and Ginsberg, 2001; Knudsen and Knudsen, 2008) . In general, oncogenic Ras subverts mitogenic signaling in the process of mediating transformation. Specifically, Ras utilizes signaling through the MEK/ERK pathway to stimulate cyclin D1 expression/function (Filmus et al., 1994; Aktas et al., 1997; Crespo and Leon, 2000) . It has been shown that oncogenic transformation through Ras in cell culture and animal models is dependent on cyclin D1 (Liu et al., 1995; Peeper et al., 1997) . Therefore, it was suggested that these two pathways function in parallel, although recent studies have proposed that loss of RB actually compromises Ras-mediated transformation and proliferation of tumor cells (DeGregori, 2006; Williams et al., 2006) . Thus, these contradictory findings suggest that further probing the intersection of oncogenic signaling and RB function may yield important insights into cooperation between coordinated tumorassociated events in cancer.
c-Myc is another widely studied oncogene that exerts a potent proliferative signal culminating in the stimulation of E2F activity (Leung et al., 2008) . However, in contrast to Ras, the c-Myc oncogene has been shown to function dominant to CDK inhibition and can lead to oncogenic transformation in a cyclin D1-independent manner (Matsumura et al., 2003) . Furthermore, unlike Ras, which mediates survival signaling, c-Myc is a potent inducer of cell death (Hoffman and Liebermann, 2008) . However, the role of RB status impinging on the biological functions related to c-Myc expression remain much less understood.
In this study, we explicitly dissected how RB loss directly influences transformed phenotype and collaborates with discrete oncogenic signals under physiologically relevant conditions to modify tumorigenic behavior and response to therapeutic intervention.
Results
Development of a genetic model for RB loss and oncogene cooperation Studies from human tumors and tumor cell lines suggest that RB deficiency could have an important role in modifying pathogenic behavior and contribute to disease progression. To examine the specific ability of RB loss to affect tumor phenotypes, models of conditional RB ablation were developed ( Figure 1a) . Initially, primary mouse adult fibrobasts (MAFs) were isolated from established RB loxp/loxp mice. Subsequently, these primary cells were spontaneously immortalized by passaging on a defined 3T3 protocol (Stengel et al., 2008) . Lastly, these 3T3 cells were stably transduced to express the activated H-Ras V12 oncogene or overexpress c-Myc. Cells progressing through the 3T3 protocol frequently acquire aberrations in p19 arf or p53 tumor suppressors, thus enabling unlimited proliferative potential. To examine the function of these signaling networks, primary cells were transduced with retroviruses encoding Ras and the relative levels of p19 arf were determined by immunoblotting (Figure 1b showed no effect of Ras expression; however, under the same conditions p53 was amply induced by exposure to the DNA-damaging agent, cisplatin (Figure 1b, right panel) . Together, these findings indicate that p19 arf activity and the response to oncogenic stress has been compromised, although the p53 protein is present and can clearly be activated in the context of genotoxic stress. As shown in Figure 1c , conditional deletion (exon 19) of the RB gene was achieved using recombinant adenovirus expressing Cre-recombinase, as documented by genomic PCR. In addition, increased protein levels of Ras and c-Myc oncogenes were readily apparent by immunoblotting in the respective transduced cell lines (Figure 1c ). 
RB loss cooperates with discrete oncogenes JL Dean et al
Oncogenic transformation by Ras and c-Myc is traditionally associated with alterations in the cytoskeletal architecture and overall cell morphology (Qian et al., 2004; Kharitonova et al., 2007) . Phalloidin staining was performed to examine F-actin structures in Rb-proficient and -deficient cells (Figure 1d ). Although 3T3 immortalized cells display typical actinstress fiber formation, Ras-and c-Myc-expressing cells displayed an altered morphology and marked disruption of the actin cytoskeleton, traditional characteristics of transformed cells. These findings suggest that expression of Ras and c-Myc was sufficient to alter the overall cell morphology of primary cells, as typically observed in transformed cell lines, and that subsequent loss of RB may have a role in exaggeration of this phenotype.
RB is well characterized as a key regulator of the G1/S transition of the cell cycle (Wang et al., 1994; Weinberg, 1995; Cobrinik, 2005; Burkhart and Sage, 2008; Knudsen and Knudsen, 2008) . Therefore, the effects of RB deletion were evaluated in the context of the immortalized, Ras-and c-Myc-expressing cultures. Strikingly, by pulse 5-bromodeoxyuridine (BrdU) labeling and flow cytometric analyses, neither RB loss nor oncogene expression resulted in a significant effect on cell cycle distribution or DNA-synthesis kinetics under conditions supportive of exponential growth (Figure 1e ). In general, it is viewed that the ability of RB to control entry into S phase is manifested through its wellcharacterized role as a transcriptional repressor (Nevins, 2001; Iaquinta and Lees, 2007) . In primary cells, RB deletion by Cre-recombinase yielded a strong deregulation of proteins whose gene expression is modulated by E2F (Figure 1f ), including cyclin A, MCM7 and PCNA. In contrast, among immortalized and oncogene-transformed cells, there was little effect of RB loss on the levels of cyclin A and PCNA. These findings indicate that the acute loss of RB may have a relatively modest role in the context of oncogenic transformation. Such a finding would be consistent with the view that during the process of transformation, the regulatory activity of RB has been effectively bypassed.
Loss of RB results in differential effects conferred by oncogene expression As both c-Myc and Ras are believed to induce a potent proliferative stimulus as part of their associated basis for transformation, the effect of RB loss on the overall cellular proliferation was determined. It was observed that RB deletion resulted in a modest proliferative advantage among immortalized populations ( Figure 2a , left panel). This effect was more potent than the induction of proliferation achieved through the expression of oncogenic Ras (comparing 3T3 RBÀ with Ras RB þ ). Loss of RB in Ras-expressing populations resulted in a modest growth advantage similar to that observed in 3T3 populations. Interestingly, c-Myc provided the most potent effect on cellular proliferation and this effect of c-Myc was dominant to the influence of RB loss (Figure 2a , right panel). Thus, loss of RB results in differential effects on cell proliferation conferred by specific oncogenes.
In general, it is well accepted that oncogenic signaling leads to proliferation under inappropriate conditions. Therefore, the ability of RB-proficient and -deficient cells to maintain proliferative potential was evaluated under conditions that are well documented to restrict proliferation. Cells transformed with oncogenic Ras exhibited an increased ability to proliferate to higher density in culture, and loss of RB cooperated with Ras to enhance this phenotype ( Figure 2b, left panel) . Surprisingly, c-Myc-expressing cells were able to achieve a similar level of density compared to 3T3 vector control cells, but overall proliferation was antagonized by RB loss (Figure 2b , right panel). To further investigate the impact of RB loss in oncogene-transformed cells, competitive proliferation assays were carried out. Specifically, RB-proficient and -deficient populations were pooled and plated in equal numbers and cultured. Over the course of four passages, the proportions of wild-type and recombined alleles in the mixed population were quantified by PCR. As shown in Figure 2c (top panels), among immortalized 3T3 cell cultures, RBdeficient cells exhibited a competitive advantage as shown by a selection against the unrecombined allele. Comparatively, in a mixed population of Ras-transformed cells, this selection was more abrupt, such that the vast majority of cells were utilizing the recombined alleles at the beginning of passage 3 ( Figure 2c , middle panels). In contrast, c-Myc-expressing cell populations modestly selected against RB-deficient cells, showing higher levels of the unrecombined allele over time ( Figure 2c , bottom panels).
As c-Myc is known to contribute to apoptosis, and loss of RB can lead to a similar predilection for cell death (Evan et al., 1992; Prendergast, 1999; Matsumura et al., 2003) , it was next investigated whether apoptosis has a role in selection against RB-deficient, c-Mycexpressing cell populations. It is believed that the proapoptotic characteristics of both c-Myc overexpression and RB loss can be attributed to E2F1 deregulation (Matsumura et al., 2003; Rogoff and Kowalik, 2004) . Accordingly, we examined the expression of E2F1, E2F2 and E2F3 protein levels in the parental 3T3 and c-Myc-transduced population (Figure 2d , left panel). It was observed that expression of c-Myc did not increase E2F2 or E2F3 protein levels, as they remained steady or nearly undetectable. However, E2F1 protein was significantly increased on c-Myc expression, although in this context RB loss had little additional effect on E2F1 levels. Among cells cultured under ideal conditions, minimal cell death was detected (data not shown). However, challenging these cells through culture in low serum resulted in a significant induction of cell death, and this phenomenon was enhanced with the loss of RB, as shown by a 2.5-fold increase in TdT-mediated dUTP nick end labeling (TUNEL) staining (Figure 2d 
RB loss cooperates with Ras-mediated tumor growth
Given that the loss of RB provided a proliferative advantage to Ras-expressing cells, the overall impact of RB loss on various parameters associated with oncogenic transformation were evaluated. First, 3T3 and Ras-transformed cells were plated in anchorage-free ( Figure 3a , left panel) and low serum (Figure 3a , right panel) conditions. Under both conditions, the combination of activated Ras expression and RB loss provided significant proliferative advantage. On extended growth past confluence, both RB-proficient and -deficient, Rastransduced cell populations were capable of forming foci; however, a 2.4-fold increase in foci numbers were observed among RB-deficient cells (Figure 3b) . Lastly, subcutaneous injection of all examined cell populations into nude mice was used to directly monitor tumor development and growth. 3T3-expressing cell populations, irrespective of RB status, failed to form tumors (Figure 3c ). Thus, loss of RB is insufficient for tumor development in the absence of additional oncogenic signals, as only the Ras-expressing populations were capable of forming xenograft tumors (Figure 3c ). These findings confirm that the parental Ras cultures were transformed and tumorigenic. In addition, the Rastransformed lines that harbored deletion of RB formed tumors at a significantly faster rate, and these tumors progressed to a larger size during the time frame of the study (Figure 3d ). These alterations in tumor size were largely attributable to enhanced cellular proliferation as monitored by BrdU incorporation (Figure 3e ), and negligible cell death was observed in the tumor sections as quantified by TUNEL analyses (data not shown). Altogether, these data indicate that, in the context of Ras expression, RB loss provides a discrete advantage for oncogenic proliferation and tumorigenesis.
Loss of RB cooperates with oncogenic Ras activation in human tumor cell lines to increase proliferation under conditions of stress A large fraction of human tumors harbor oncogenic Ras mutations. To determine whether the findings from the mouse fibroblast model system were valid in discrete human tumor models, the impact of RB loss in HT1080 (fibrosarcoma) and HepG2 (hepatoma) cell lines, both of which harbor activating Ras mutations and functional RB pathways, was explored. To produce isogenic lines with variant RB status, cells were transduced with retroviruses producing a short-hairpin RNA against RB or a nonspecific scrambled control. RB knockdown was confirmed in selected polyclonal populations by immunoblotting ( Figure 4a ). Interestingly, in these cell lines, the loss of RB expression was accompanied by enhanced levels of only specific E2F-regulated proteins (for example, RNRII, but not cyclin A or MCM7) (Figure 4a ). This corresponded to a modest increase in extended growth rate with the loss of RB (Figure 4b ). These cell lines showed an increased rate of proliferation as monitored by anchorage-independent growth (Figure 4c ). In addition, when grown in low serum, RB-depleted HT1080 cells exhibited enhanced proliferative rates relative to RB-proficient controls (Figure 4d ), which was not observed among HepG2 populations. Together, this implies that additional signaling events may be necessary for acquisition of this particular transformed characteristic. Finally, to evaluate tumorigenesis, xenograft injections into nude mice were carried out, showing that RB-deficient HT1080 cell tumors grew significantly faster than their RB-proficient counterparts (Figure 4e ). Taken together, these data recapitulate results observed from the fibroblast model, and further reinforce a cooperative relationship between the expression of Ras and loss of RB in providing a discrete proliferative advantage under physiologically relevant conditions.
Influence of the RB pathway on therapeutic response of Ras-transformed cells As RB deficiency results in disparate responses with regard to cooperation with oncogenic signaling and can result in increased susceptibility to cell death, we investigated whether there were specific means to intercede in exploiting loss of RB function among such tumors. Particularly, loss of RB has been shown to result in a proclivity toward cell death mediated by p53 (Morgenbesser et al., 1994) . In addition, there is evidence for cooperation between increased E2F activity and exposure to Nutlin-3a leading to increased rates of p53-mediated apoptosis (Kitagawa et al., 2008) . Proteins were harvested from exponentially growing cells and subjected to immunoblot for RB and downstream target proteins. Lamin B was used as a loading control. (b) Equal numbers of miRB-and miNS-infected cells were plated and subsequently counted every 48 h using trypan blue exclusion. (c) Cells were seeded in anchorage-free conditions and counts were performed 96 h later using trypan blue exclusion. **Po0.01, ***Po0.001 (d) Cells were grown in low serum (0.2% fetal bovine serum (FBS)) for 96 h. Cells were counted using trypan blue exclusion. ***Po0.001. (e) miRB and miNS expressing HT1080 cells were injected contralaterally into nude mice. Tumor volume was calculated using calipers. *Po0.05.
Initially, Ras-expressing MAFs were exposed to 5 mM and 10uM Nutlin-3a for 72 h and processed for cell cycle analysis (Figure 5a ). Although RB-proficient cells arrested in G1 phase of the cell cycle on treatment, RB-null cells arrested primarily in the G2/M phase. Thus, RB-proficient cells maintain a largely 2N DNA content throughout the course of drug treatment, whereas RB-deficient cells accumulate a predominately 4N DNA content with increasing concentration of Nutlin-3a treatment (Figure 5b) . Although RB-proficient cells showed cessation of cell cycle progression, rates of apoptosis did not significantly change through increased Nutlin-3a dosage, as monitored by propidium iodide staining. (Figure 5c ). Interestingly, RB-null cells showed significantly increased apoptosis in a dosedependant manner with Nutlin-3a treatment. These data suggest that although RB loss, in cooperation with Ras-mediated transformation, promotes enhanced cell proliferation and tumorigenesis, treatment of these cells with therapeutic compounds targeting the p53 pathway results in increased sensitivity and cell death dependent on p53-mediated apoptosis.
Discussion
The results described herein indicate that the loss of RB exhibits a highly context-dependent effect relative to cellular transformation. Although there is little evidence for an effect of RB loss under idealized conditions, stresses associated with tumorigenesis uncover a pronounced and significant role for the loss of RB. Strikingly, these functions of RB were strongly modified, not just by the cellular environment, but through the cooperating oncogene. Thus, consideration of underlying pathways of antagonism/cooperation can provide specific insight into the treatment of RBdeficient disease. In this regard, characterization of our 3T3 immortalization process revealed a deficiency in p19 arf regulation, which is a frequently documented aberration resulting from this spontaneous immortalization protocol. This lesion bypasses the cellular senescence response that occurs as a result of oncogene activation. Thus, this model provides a key opportunity to elucidate secondary roles of RB in modifying the transformed phenotype.
Initial investigations into the effects of RB loss showed that the biochemical effect of this deficiency is partially masked during the process of transformation, but can be uncovered through exposure to various cellular stresses frequently associated with tumorigenesis. Previous studies have shown that the deletion of RB in primary fibroblasts induces an appreciable deregulation of E2F-mediated target genes (Stengel et al., 2008) . This effect of RB on gene expression is readily observed with both acute and chronic loss of RB. However, on immortalization/transformation, the effect of RB loss on target genes is compromised, as the levels of a number of the E2F-target genes are deregulated as a consequence of immortalization. This failure to exert a dominant effect is recapitulated in the examination of cell cycle kinetics, wherein RB loss mediates a minimal effect on cell cycle distribution and rates of BrdU incorporation. At face value, these results suggest a surprisingly insignificant role for RB in the regulation of proliferative programs and cell cycle machinery in immortalized/transformed cell populations. However, physiological proliferative responses are typically constrained by a plethora of antiproliferative mechanisms that contribute to the maintenance of tissue homeostasis. Through exposure to competitive proliferation, limiting mitogen, an anchorage-free environment, and growth at high density, the effects of RB loss became strikingly apparent. Under all of these conditions, the loss of RB significantly promoted cellular proliferation beyond traditional antiproliferative barriers. Critically, tumorigenic proliferation is restrained in the animal by a number of such barriers, and we observed that loss of RB had a pronounced impact on tumorigenic proliferation. In total, these studies suggest that the impact of RB can have dramatic effects on tumorigenic proliferation that are not merely reflective of an increased steady state level of E2F-target genes and altered cell cycle kinetics.
It is well appreciated that human tumorigenesis reflects combinations of oncogene activation and loss of tumor-suppressor pathways that cooperate in mediating the transformed phenotype (Hanahan and Weinberg, 2000) . Given the critical role of RB in cell cycle progression, it could be surmised that RB loss would cooperate with virtually all oncogenes capable of driving cell cycle machinery. Surprisingly, this was not the case within our model system. Although the c-Myc oncogene gave rise to rapid proliferation, and RB loss could be tolerated in this context, there was a selection against RB deficiency in c-Myc-expressing cultures. Interestingly, the expression of c-Myc was accompanied by an upregulation of specifically E2F1, which has been previously described to be pro-apoptotic in specific circumstances (Rogoff and Kowalik, 2004) . It is possible that this increase in E2F1 has primed the c-Mycexpressing populations for apoptosis, which is further exacerbated when the negative regulatory effects of RB on E2F1 are lost. Furthermore, this effect of RB loss could be exaggerated in the context of stresses in which c-Myc is prone to induce cell death. Thus, these findings suggest that there are intrinsic physiological conditions under which loss of RB does not provide a clear advantage to tumor cells. Interestingly, recent literature has suggested a surprising requirement for RB in Rasmediated transformation (Williams et al., 2006) . This role for RB seems counterintuitive given the previously documented role for RB deficiency in promoting escape from facets of Ras-mediated senescence (Serrano et al., 1997) . In fact, our data show that genetic deletion of RB will exacerbate Ras-mediated tumorigenesis. Particularly, this effect was most striking in the context of tumorigenic growth in both mouse and human tumor xenograft models, suggesting that loss of RB function could be a particularly important event in the progression of Ras-initiated tumors. These contradictory findings, suggest that cellular context/experimental conditions could have significant effects on the interpretation of data. Consistent with this concept, in C-cell thyroid tumorigenesis, loss of RB leads to aberrant induction of N-Ras activity that can restrict tumorigenesis by inducing senescence (Shamma et al., 2009) . However, in this context the loss of p19 arf facilitates RBdependent transformation. Thus, the genetic milieu and tissue context are both likely modifiers of the interactions between RB and oncogenic pathways.
Our studies focused on exacerbation of existing tumorigenic phenotypes-that is, disease progression, and in this context are consistent with several animal models of Ras-mediated tumorigenesis wherein RB loss exacerbates the tumor phenotype Ho et al., 2009) . Particularly, in a two-stage chemical skin carcinogenesis model, induction of DNA-damage response by direct carcinogen (DMBA) exposure or Ras activation was shown to increase the rates of acute p53-mediated apoptosis in an RB-deficient setting, ultimately limiting disease initiation (Ruiz et al., 2005; Lara et al., 2008; Santos et al., 2008) . However, in this same setting, RB deficiency was shown to increase the rates of malignant conversion to carcinoma, implicating a role for RB in tumor progression. In addition, these data are in agreement with previous reports, which implicate RB deficiency in sensitizing to DNA damage-induced cell death. Importantly, in the DMBA-induced skin carcinogenesis model, it was observed that on RB loss, levels of the pocket protein p107 were increased, a reduction in which resulted in increased susceptibility to Ha-Rasinduced transformation, implying a compensatory role for p107 and RB in the cell cycle response to DNA damage/oncogene activation . Interestingly, only singular loss of RB resulted in an increased percentage of malignant conversion, suggesting that the impact of this tumor suppressor in disease progression may be particularly relevant.
These findings suggest that tumors harboring RB deficiency could be particularly aggressive, ultimately necessitating effective approaches to specifically exploit the loss of RB for therapeutic intervention. The proapoptotic effects of c-Myc are generally elicited through the p53 pathway (Hermeking and Eick, 1994; Wagner et al., 1994) . Thus, the finding that RB deletion sensitized cells to c-Myc-mediated cell death suggested that induction of p53 function may represent a key means to therapeutically capitalize on RB loss. Correspondingly, in a variety of settings, it has been shown that therapeutic agents that function through DNA damage signaling, and thus activate p53, can be particularly effective in RB-deficient tumors. The Nutlin-3a compound disrupts the MDM2/4-p53 interaction and stabilizes the levels of p53 (Shangary and Wang, 2009 ). Exposure to Nutlin-3a resulted in a highly RB-dependent cell cycle blockade, wherein RB-proficient cultures arrested with a pronounced 2N DNA content, and the majority of RB-deleted cells arrested with a pronounced 4N DNA content. This G2/M arrest was accompanied by a significant increase in cell death in RB-deficient cultures, indicating that RB proficiency was providing protection to the Ras-transformed cells.
Such findings are consistent with other models, wherein it has been suggested that RB deficiency sensitizes to p53-mediated cell death (Macleod et al., 1996) and suggests additional therapeutic strategies for the treatment of highly aggressive tumors.
Altogether, these findings highlight the highly context-dependent consequence of RB loss on tumor cell biology that has implications for both tumor progression and therapeutic interventions.
Materials and methods

Cell lines and expression constructs
Primary adult fibroblasts (MAFs) were generated from the peritoneal fascia of Rb loxp/loxp mice as previously described (Marino et al., 2000) . Immortalized Rb loxp/loxp MAFs (3T3) were generated using the 3T3 protocol for spontaneous immortalization. 3T3 MAFs were then transformed through stable transfection of an H-Ras V12 expression vector as previously described (Stengel et al., 2008) . The H-Ras V12 expression vector was generously provided by J Wang (University of California, San Diego). Transfected cells were selected using puromycin, and subsequent populations were propagated. In addition, c-Myc MAFs were generated by infecting 3T3 MAFs with c-Myc encoding pMX-based retroviral constructs. c-Myc-green fluorescent protein (GFP) and vector-GFP constructs were a kind gift from Y Zheng (Cincinnati Children's Hospital Medical Center). Retroviral vector pMSCV-LMP-miRB was a kind gift from Dr Scott Lowe (Cold Spring Harbor Laboratory). This vector expresses short-hairpin RNA-targeting nucleotides 699-719 of human RB (5 0 -GCAGTTCGATATCTACTGAAA-3 0 ) in an miR30 background. To generate the nonspecific control (miNS), pMSCV-LMP-miRB was digested at the XhoI and EcoRI sites to remove RB-targeting coding sequence. It was replaced with nonspecific targeting sequence short-hairpin RNA (5 0 -GCTGAGG TGATAAACAGTTACA-3 0 ) using the same XhoI and EcoRI sites, as per the manufacturer's instructions (Open Biosystems, Huntsville, AL, USA). Retroviral packaging and preparation was performed by the Viral Vector Core of Cincinnati Children's Research Foundation (Cincinnati Children's Hospital Medical Center) using 10 mg of each vector DNA.
Cell culture and viral infections
Mouse fibroblast and human cell cultures were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (FBS), 100 U/ml penicillin/streptomycin and 2 mM L-glutamine at 37 1C and 5% CO 2 . Replication-defective recombinant adenovirus expressing GFP (Ad-GFP) or expressing both GFP and Cre-recombinase (Ad-GFP-Cre) were obtained from G Leone (Ohio State University). Conditional RB knockout was achieved in primary, 3T3, Ras and c-Myc Rb loxp/loxp MAFs through Ad-GFP-Cre infection, with Ad-GFP infection serving as a control. Infection efficiency was monitored through GFP expression, and was determined to be >90% by immunofluorescence. Cells were cultured for at least 4 days after adenoviral infection before use, although the passage number and length of time after infection remained consistent throughout all experiments. All cell lines were used within 10 passages of adenoviral infection. Retroviral infections were performed by exposing cells to a 1:1 ratio of 1 ml virus: 8 mg/ml polybrene for a minimum of 6 h. After which, cells were washed twice with 1 Â phosphate-buffered saline and returned to normal medium. miRB-and miNS-infected cells were selected in 2.5 mg/ml puromycin for a minimum of 7 days. c-Myc-infected cells were selected by fluorescenceactivated cell sorting through GFP expression. 
PCR
Immunoblot analysis
Cell lysates were resolved by SDS-polyacrylamide gel electrophoresis and transferred to Immobilon-P membrane (Millipore, Billerica, MA, USA). Proteins were detected using the following primary antibodies: Santa Cruz Biotechnology 
Flow cytometric analysis
Cells were harvested and fixed in 70% EtOH overnight at 4 1C. Cells were prepared for flow cytometry as previously described (Stengel et al., 2008) . Cell cycle analysis was carried out using FlowJo 8.8 software. BrdU data are represented as a percentage of total population.
Cell growth experiments
Low serum growth experiments were conducted in normal growth medium with a lower concentration of FBS (0.2%). Equal numbers of cells (1 Â 10 5 ) were plated in normal serum (10% FBS) for a period of 12 h. After 12 h, normal serum media was removed and cells were washed three times with low serum media (0.2% FBS) to remove extraneous serum. Cells were allowed to grow in low serum media for 96 h. Anchorageindependent growth was facilitated through plating equal numbers (1 Â 10 5 ) of cells into non-coated Petri dishes. Cells were allowed to grow for 96 h. Growth post-confluence was examined by plating 1 Â 10 6 cells into 10-cm culture dishes (B90% confluent). Cells were allowed to grow for 144 h. Total live cells were counted using trypan blue exclusion.
Xenografts and immunohistochemistry
In all, 1 Â 10 6 cells were injected subcutaneously into the flanks of 6 to 8-week-old athymic nude mice (Harlan SpragueDawley, Indianapolis, IN, USA). Cells were suspended in 150 ml phosphate-buffered saline and 50 ml Matrigel (BD Biosciences, San Jose, CA, USA). Tumor growth was monitored using calipers. Tumor volume was determined using the following equation: v ¼ q(width 2 Â length)/6. At 2 h before euthanization, mice were injected intraperitoneally with 150 mg/kg BrdUrd in 100 ml 0.9% saline. Tumors were excised, fixed and paraffin-embedded for sectioning. All animal experiments were conducted in accordance with the National Institute of Health Guide for Care and Use of Laboratory Animals. Tumor section preparation, BrdUrd and TUNEL staining was performed as previously described (Zagorski et al., 2007) .
Immunofluorescence Cells were plated on coverslips and allowed to adhere overnight. Cells treated with low serum conditions (0.2% FBS) were cultured for 96 h. Cells were then fixed in 3.7% formaldehyde and permeablized in 0.4% Triton X-100 for 20-30 min at room temperature. For TUNEL assay, cells were labeled and stained using the DeadEnd Tunel System (Promega, Madison, WI, USA) as per the manufacturer's instructions. Phalloidin staining was also performed according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA; Molecular Probes, Eugene, OR, USA). All immunoflourescence was counterstained with 4,6-diamidino-2-phenylindole for visualization of nuclei.
Drug treatments
Cells were plated in equal numbers and allowed to adhere for 24 h. Nutlin-3 was reconstituted in dimethylsulfoxide (DMSO) as per the manufacturers instructions (Cayman Chemical, Ann Arbor, MI, USA) and was added to normal growth medium at final concentrations of 5 and 10 mM. DMSO was added to untreated controls at a volume equal to that of 10 mM treatments. Treatments were carried out for 72 h, at which time cells were labeled with BrdUrd (Amersham Pharmacia Biotech, Piscataway, NJ, USA) for 1 h. Cisplatin treatment was carried out by exposing cells to a 4 mM concentration for 24 h. Cells were prepared for bivariate (BrdUrd vs propidium iodide) flow cytometry as previously described.
Statistical analysis
All statistical analyses were carried out with GraphPad Prism (GraphPad Prism Software). P-values were calculated by performing Student's t-tests.
